Tag - LUCD

Executive Moves

Lucid appoints policy leader Danielle Scelfo as SVP, Market Access & Gov’t Affairs

Lucid Diagnostics (NASDAQ: LUCD) announced the appointment of Danielle Scelfo as SVP, Market Access & Government Affairs, reporting to the CEO. With more than 25 years of strategic and operational experience across...

September 16, 2025

Developments

Lucid reports positive data from ESOGUARD BE-1 study in BE and EAC patients

Lucid Diagnostics (NASDAQ:LUCD) announced positive results from its clinical validation study of EsoGuard Esophageal DNA test on samples collected from patients with Barrett’s Esophagus (BE) and esophageal...

July 5, 2024

Markets

Analysts start Lucid Diagnostics at buy: PTs $14, $18

Analysts for BTIG and Canaccord Genuity launched coverage of Lucid Diagnostics (NASDAQ:LUCD) with “buy” ratings and price targets of $14 and $18, respectively. The stock closed at $9.52 on Oct. 5. Lucid recently...

November 8, 2021

Tag - LUCD

Lucid appoints policy leader Danielle Scelfo as SVP, Market Access & Gov’t Affairs

Lucid reports positive data from ESOGUARD BE-1 study in BE and EAC patients

Analysts start Lucid Diagnostics at buy: PTs $14, $18

Subscribe